Modern Immunotherapy in BCG-Unresponsive, BCG-Relapsing and High Risk BCG-Naive Non-Muscle Invasive Urothelial Carcinoma of the Bladder | ClinicalTrials HQ

Ask about research services

Swipe the table sideways for more columns.

Trial	Conditions	Status	Phase	Updated	More info	NCT ID
Modern Immunotherapy in BCG-Unresponsive, BCG-Relapsing and High Risk BCG-Naive Non-Muscle Invasive Urothelial Carcinoma of the Bladder	Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Male Urogenital Diseases, Neoplasms by Histologic Type, Neoplasms by Site, Non-Muscle Invasive Bladder Neoplasms, Urogenital Diseases, Urogenital Neoplasms, benign urinary system neoplasm, carcinoma, epithelial neoplasm, neoplasm, transitional cell carcinoma, urinary bladder cancer, urinary bladder disorder, urinary bladder neoplasm, urinary system disorder, urothelial carcinoma	Active, not recruiting	Phase 1 / Phase 2	2026-07-15		NCT03317158

4 results · Page 1 of 1

Swipe the table sideways for more columns.

Organizations	Linked trials
AstraZeneca	806
Hoosier Cancer Research Network	7
ImmunityBio, Inc.	28
Noah Hahn, M.D.	1

9 results · Page 1 of 1

Swipe the table sideways for more columns.

Research sites	City	Country	Linked trials
BCG Oncology	Phoenix	United States	2
Columbia University Irving Medical Center	New York	United States	234
Fox Chase Cancer Center	Philadelphia	United States	259
Indiana University Melvin and Bren Simon Cancer Center	Indianapolis	United States	17
Johns Hopkins University: Sidney Kimmel Comprehensive Cancer Center	Baltimore	United States	1
University of Iowa Hospitals and Clinics	Iowa City	United States	99
University of Nebraska Medical Center	Omaha	United States	397
University of North Carolina at Chapel Hill	Chapel Hill	United States	129
Washington University School of Medicine	St Louis	United States	895